The EIB will lend up to EUR 20m to PAION AG, a German pharmaceutical company specialised in anaesthesia and sedation drugs. The Aachen-based company is currently developing ‘remimazolam’, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for use in procedural sedation, general anaesthesia and intensive care unit (ICU) sedation.

Subscribe to The Financial Analyst to get original opinion and all the latest news on trending financial topics and breaking stories related to analysis and global markets. If you have a tip or a financial opinion to share get in touch to submit your story.